Ustekinumab (Stelara; Janssen Biotech Inc.) for treatment of psoriatic arthritis
Record ID 32016000798
Authors' recommendations: Description of Technology: This report focuses on the use of ustekinumab (Stelara) for treating psoriatic arthritis (PsA). Patients with psoriasis are treated by a dermatologist and are usually referred to a rheumatologist when symptoms of PsA develop. Ustekinumab is administered by subcutaneous injection. It is available as single-use vials or prefilled syringes at 45 milligrams (mg) per 0.5 milliliters (mL) or 90 mg/mL. The recommended initial dose is 45 mg, followed by another dose of 45 mg 4 weeks after the first dose, and then a 45-mg dose every 12 weeks thereafter. Patients who have concomitant moderate to severe plaque psoriasis and weigh more than 100 kilograms (220 pounds) may receive 90 mg initially, at 4 weeks after the first dose, and then every 12 weeks thereafter. Ustekinumab may be administered in a clinic or in the patient's home. With proper training, patients may self-administer ustekinumab at the discretion of the physician. Patient Population: Ustekinumab is indicated for the treatment of adult patients ( 18 years of age) with active PsA, alone or in combination with methotrexate.
Project Status: Completed
Year Published: 2016
URL for published report: The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=16052
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
- Antibodies, Monoclonal, Humanized
- Arthritis, Psoriatic
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: 2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.